Subjects will be enrolled into the Screening period, which will last up to 28 days. Once all eligibility criteria are confirmed, subjects will receive the IP as a 2-week supply of capsules with tenofovir given as a 4-week supply. Subjects will be required to take the IP per protocol for 12 weeks. During the 12-week treatment period, subjects will return to the clinic at biweekly intervals, except when beginning IP administration, for safety assessments including physical examination and laboratory sample analysis of chemistry, hematology, and urine. Sample collection for Locarnini biomarkers will occur at Day 1; Weeks 2, 4, 8, 12, and 14; and at the End of Study Visit. Sample collection for cytokine levels and other biomarkers of immune response and plasma samples will also occur at predose on Day 1 and at Weeks 6 and 12. Sample collection for population PK analysis will also be collected predose on Day 1, 2 hours postdose on Day 1, and at Weeks 4, 8, and 12.